We focus on gain-of-function compounds whose mechanisms rely on induced proximity.

We have interests in targeted protein relocalization, chemical control of epigenetic machinery, and in-silico drug discovery.

We hope to uncover additional mechanistic underpinnings of oncogenic transformation.

We have interests in identifying cancer driver genes missed by traditional genomic identification strategies.

We use the tools of chemical biology and deep insights into cancer biology to design new therapeutics.

We have interests in directly drugging TP53 mutations and other tumor suppressors.

We are interested in developing technologies to address the world’s most pressing problems that might have a long-run impact. In particular, we are interested in technology solutions for cancer prevention, and to help mitigate the risk of global catastrophic biological risks.